Changing to Avastin could save NHS £100m a year

Changing to Avastin could save NHS £100m a year

Posted on 25th November 2014

The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.

eye-care

Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.

It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.


Related Posts

Eyewear boutique summer event

23rd June 2017

Last night we held our summer frame preview event in our independent eyewear boutique. Thank you to all who attended. We loved seeing so many guests experimenting with different styles and looking utt...

Read more

We’ve been shortlisted for another award

09th June 2017

We're thrilled to learn Ian Cameron has been shortlisted for the BCLA's (British Contact Lens Association) Dry Eye Award. For those who have experienced dry eye (ocular surface disease), you will know...

Read more

Cameron Optometry represented at conference for international contact lens specialists

08th June 2017

Former managing director and founder of Cameron Optometry, Donald Cameron, attended the International Society of Contact Lens Specialists (ISCLS), along with Ian Cameron. Here Donald shares some of th...

Read more

Practice manager Carol completes the Edinburgh Marathon (by accident!)

29th May 2017

For patients of the practice, you will know Carol Field, our dispensing practice manager. On Sunday Carol did something amazing. Carol completed the Edinburgh Marathon. The reason this is a particula...

Read more